A Phase II Study of Anecortave Acetate for the Treatment of Exudative Age-Related Macular Degeneration

The purpose of the study is to determine the concentration of anecortave acetate (15 or 30 mg versus placebo) that is safe and effective for the inhibition of the growth of blood vessels in the retina in patients with wet AMD.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

AMD

Age range

50 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Ages 50 years and over
Other protocol-defined inclusion and exclusion criteria may apply.

Treatment and study plan

Anecortave acetate 30 mg

Drug

0.5ml administered onto the sclera once every six months for 24 months

Anecortave Acetate 15 mg

Drug

0.5ml administered onto the sclera once every six months for 24 months

Anecortave Acetate 3 mg

Drug

0.5ml administered onto the sclera once every six months for 24 months

Anecortave Acetate Vehicle

Other

0.5ml administered onto the sclera once every six months for 24 months

Primary outcomes

Mean change in logMAR visual acuity at 12 months from baseline.

Time frame: 12 months

Sponsors and collaborators

Lead sponsor

Alcon Research

Industry

Registry information

Important dates

Study start: 1999
Primary completion: 2003
Study completion: 2003
First posted: Jul 4, 2006
Registry last updated: Mar 6, 2012

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed